MannKind Corporation (MNKD) Rises 20% Following FDA Approval of Afrezza for Pediatric Use
Since receiving FDA approval to expand its inhaled insulin product Afrezza to children and adolescents aged six and older, MannKind Corporation's stock has risen by approximately 20%. The company is also supported by a recent grant from Breakthrough T1D for further clinical trials. Analysts project over 54% upside potential based on current price targets.
Tickers: $MNKD
Topics: diabetes treatment pharmaceuticals stock performance